AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31393399
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg or Anastrozole 1 mg once a day
Trial: 19095871
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Trial: 19095871
Drug: 0.4% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Trial: 11116103
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg)
Trial: 8322135
Drug: Open vaginal
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open vaginal vault method with preoperative cefonicid administration
Trial: 3524970
Drug: Diflunisal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500 mg twice daily)
Trial: 3524970
Drug: Phenylbutazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (200 mg twice daily)
Trial: 27863806
Drug: ABT‐493 25-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐493 25-800 mg (single doses)
Trial: 27863806
Drug: ABT‐493 200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐493 200-800 mg (multiple doses)
Trial: 27863806
Drug: ABT‐493 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐493 (all doses)
Trial: 24950985
Drug: Trebananib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib (15 mg/kg) plus weekly intravenous paclitaxel (80 mg/m²)
Trial: 24950985
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus weekly intravenous paclitaxel (80 mg/m²)
Trial: 24950985
Drug: Trebananib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib (15 mg/kg)
Trial: 17087311
Drug: Vitamin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin treatment
Trial: 26423732
Drug: Garlic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic treatment
Trial: 19417716
Drug: MDMA (ecstasy)
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (ecstasy) administration in humans
Trial: 19417716
Drug: MDMA (ecstasy)
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (ecstasy) administration in squirrel monkeys
Trial: 19417716
Drug: MDMA (ecstasy)
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (ecstasy) administration in both species
Trial: 17853767
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Tetracycline and external application of Cuochuangping Ointment
Trial: 11182474
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tiagabine
Trial: 9164315
Drug: Eptifibatide 135
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 135 micrograms/kg bolus followed by 0.5 microgram kg‐1 min‐1 infusion for 20‐24 h
Trial: 9164315
Drug: Eptifibatide 135
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 135 micrograms/kg bolus followed by 0.75 microgram kg‐1 min‐1 infusion for 20‐24 h
Trial: 9164315
Drug: Eptifibatide treatment
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide treatment
Trial: 24666767
Drug: IV clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clonidine 2 mcg·kg(‐1)
Trial: 24666767
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl 2 mcg·kg(‐1)
Trial: 22092081
Drug: Low-dose double-blind
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose double-blind placebo-controlled food challenge (DBPCFC) using a standardized vehicle with eight titrated protein doses from 3 μg to 1 g
Trial: 30582717
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.05% ointment
Trial: 1444880
Drug: Acetyl levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetyl levocarnitine hydrochloride (2.5 g/d for 3 months followed by 3 g/d for 3 months)
Trial: 20012550
Drug: Anti-TNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF treatment (group 1, n=23)
Trial: 20012550
Drug: NSAIDs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs treatment (group 2, n=24)
Trial: 2752716
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg lomefloxacin, given orally twice daily for 2 weeks
Trial: 2752716
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to four subjects
Trial: 793549
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (aortocoronary bypass)
Trial: 25982678
Drug: Thiamine supplementation
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine supplementation (3 × 100 mg/day for six weeks)
Trial: 15624735
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and blue light (405-420 nm) for 15 minutes
Trial: 15624735
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and intense pulsed light (IPL, 500-1,200 nm)
Trial: 10843478
Drug: Colposcopy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colposcopy after therapy
Trial: 9171795
Drug: Coaxial catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaxial catheter method for sequential spiral CT during arterial portography (CTAP) and hepatic arteriography (CTA)
Trial: 9171795
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CTAP and CTA
Trial: 3281786
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil alone at a dose of 80 mg three times daily
Trial: 3281786
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 40 mg of verapamil three times daily with 0.25 mg of digoxin daily
Trial: 28555092
Drug: Tetrodotoxin (TTX)
RxNorm normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrodotoxin (TTX) 30 μg subcutaneously twice daily for four consecutive days
Trial: 28555092
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously twice daily for four consecutive days
Trial: 21646935
Drug: Vestipitant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestipitant and Paroxetine combination
Trial: 17070157
Drug: Probucol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1 g/d)
Trial: 14628586
Drug: Acupuncture (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (AC) combined with drug therapy
Trial: 14628586
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug therapy
Trial: 10902992
Drug: E =
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E = 1171 kJ + 12 mg iron
Trial: 10902986
Drug: M =
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: M = 209 kJ + 12 mg iron
Trial: 24028708
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium dialysate (1.25 mmol/L)
Trial: 24028708
Drug: Standard calcium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard calcium dialysate (1.75 mmol/L)
Trial: 22376791
Drug: Rest therapy
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest therapy for 10 weeks with a recommendation to rest for two hours daily and the option of using a flexible lumbar belt
Trial: 22376791
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy once a week for 10 weeks
Trial: 20888994
Drug: Chemotherapy (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fludarabine and cyclophosphamide)
Trial: 18391846
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment for 3 months
Trial: 11964956
Drug: 0.4 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/dL oligosaccharides
Trial: 11964956
Drug: 0.8 g/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/dL oligosaccharides
Trial: 10214007
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion for 2 postoperative days (group B 2)
Trial: 10214007
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion for 4 postoperative days (group B 4)
Trial: 29510745
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell vaccines (DCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Trial: 29510745
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor cell vaccines (TCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Trial: 26828571
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training plus work therapy (n = 15)
Trial: 26828571
Drug: Work therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work therapy alone (n = 16)
Trial: 7851108
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment E
Trial: 7851108
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment S
Trial: 3132551
Drug: Flumazenil (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.10 mg/kg)
Trial: 3132551
Drug: Flumazenil (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.20 mg/kg)
Trial: 25640664
Drug: Prednisolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (50 mg for 10 days)
Trial: 19968391
Drug: Best practice
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practice treatment conditions
Trial: 12217455
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol
Trial: 12217455
Drug: High-dose alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alcohol
Trial: 7994447
Drug: Hydrochlorothiazide 3
RxNorm normalized name: hydrochlorothiazide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 3 mg
Trial: 7994447
Drug: Hydrochlorothiazide 6
RxNorm normalized name: hydrochlorothiazide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 6 mg
Trial: 14686231
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy
Trial: 28683833
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact (SSC) for at least one continuous hour daily for 5 weeks
Trial: 20039456
Drug: Acupuncture (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (once daily, starting on postoperative day 1, for up to six consecutive days)
Trial: 11821089
Drug: Ellios pessaries
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ellios pessaries (2 times 200‐mg pessary/day)
Trial: 11821089
Drug: Utrogestan capsules
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Utrogestan capsules (2 x 100‐mg capsules, two times a day)
Trial: 2475688
Drug: Slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release verapamil (SR) 240 mg q.i.d.
Trial: 2475688
Drug: Immediate-release verapamil
RxNorm normalized name: verapamil Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release verapamil (IR) 80 mg t.i.d.
Trial: 2475688
Drug: Immediate-release verapamil
RxNorm normalized name: verapamil Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release verapamil (IR) 480 mg/day
Trial: 23731168
Drug: Naftopidil (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (75 mg/day)
Trial: 23731168
Drug: Silodosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (8 mg/day)
Trial: 31741279
Drug: Tablet animation
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet animation format of the CHU-9D questionnaire
Trial: 31741279
Drug: Tablet image
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet image format of the CHU-9D questionnaire
Trial: 27241836
Drug: Aspirin supplementation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin supplementation
Trial: 19193422
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 1)
Trial: 19193422
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 2)
Trial: 15296472
Drug: Surgical and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical and/or medical therapy for acromegaly
Trial: 15296472
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (noncontrolled patients)
Trial: 9059403
Drug: Iodixanol (13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (13.5 g I)
Trial: 9059403
Drug: Iopromide (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (15.0 g I)
Trial: 3767008
Drug: Oral ranitidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ranitidine, 150 mg, with 150 ml water
Trial: 3767008
Drug: Oral ranitidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ranitidine, 150 mg, with no further fluid
Trial: 3829296
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 150 ml water
Trial: 3767008
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml water with placebo
Trial: 30267481
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Surgicel and histamine‐2 receptor antagonist (H2 RA)
Trial: 30267481
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with a proton pump inhibitor (PPI)
Trial: 30267481
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Surgicel and H2 RA
Trial: 27727157
Drug: Single-dose maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose maraviroc 300 mg
Trial: 24850603
Drug: α‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐lipoic acid (600 mg/day) in addition to basic therapy
Trial: 22842339
Drug: BDP/FF 100/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF 100/6 μg in pressurised metered-dose inhaler (pMDI) extrafine formulation
Trial: 22842339
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 μg pMDI
Trial: 12718708
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DB and PLB (CB)
Trial: 10325912
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (budesonide 600 micrograms daily)
Trial: 9061129
Drug: Gericomplex (ginseng,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gericomplex (ginseng, vitamins, minerals and trace elements) - 2 capsules daily for 8 weeks
Trial: 9061129
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules - identical in appearance to Gericomplex
Trial: 31343585
Drug: Weekly unsupervised
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly unsupervised WCD-guided 6MWTs at home
Trial: 28497756
Drug: S-1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80 mg/m2, 80-120 mg per day, twice daily for 28 days)
Trial: 24439462
Drug: Intravitreal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal therapy using ranibizumab (n = 11)
Trial: 24439462
Drug: Intravitreal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal therapy using bevacizumab (n = 20)
Trial: 24439462
Drug: Intravitreal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal therapy using triamcinolone (n = 19)
Trial: 24439462
Drug: Intravitreal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal therapy (all types combined)
Trial: 19178624
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: metal matrix containing two implants
Trial: 11442739
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg bid
Trial: 9439561
Drug: Sulfonylurea therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea therapy (gliclazide, ≤ 160 mg.d‐1)
Trial: 9439561
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (double-blind placebo or no tablets)
Trial: 2438647
Drug: PCOP combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCOP combination for 6 months followed by chlorambucil or CVP for 12 months
Trial: 2438647
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of interferon and chemotherapy (proposed for future trials)
Trial: 26936907
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily
Trial: 28690028
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) with or without intravenous immunoglobulin (IVIG)
Trial: 22424400
Drug: Cognitive-behaviour group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour group therapy (15-week manualized group therapy)
Trial: 22424400
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list (4 months without treatment)
Trial: 18582254
Drug: mannitol 0.5
RxNorm normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mannitol 0.5 g.kg(‐1)
Trial: 18477268
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution (control)
Trial: 11821704
Drug: High-sodium tap
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium tap water (HSTW) with sodium concentration of 196 mg/l (8.5 mmol/l)
Trial: 11821704
Drug: Low-sodium mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium mineral water (LSMW) with sodium concentration of 32 mg/l (1.4 mmol/l)